Search in the Abstract Database

Search Abstracts 2015

* = Presenting author

N003 Quality of life improves after intravenous iron treatment - but not if inflammation is present

R. Edelbo Rasmussen*, A. Schlott, P. Bager

Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark

Background

Having inflammatory bowel disease (IBD) increases the risk of anaemia and/or iron deficiency. Intravenous administration of iron supplementation is often chosen when treatment in given.

Intravenous iron have proven good effect on correcting both anaemia and iron deficiency. However, the effect on the patients' health-related quality of life (HRQoL) has only slightly been investigated. Some patients expect a rapid effect on HRQoL parameters (such as less fatigue) after iron infusions. Can iron infusions fulfil this expectation?

The aim of this study was to investigate outpatients HRQoL before and after intravenous iron infusions.

Methods

60 outpatients treated at the Department of Hepatology and Gastroenterology, Aarhus University Hospital, filled in a 10 item questionnaire regarding HRQoL before intravenous iron infusion and 12 weeks after. Furthermore demographics and disease related data were collected, including blood samples.

A matched group from the background population (n = 60) was used as controls regarding the HRQoL questionnaires.

Results

The mean iron dose given was 1000 mg and the mean increase in haemoglobin levels were 2 g/dl at week 12. All HRQoL parameters improved significantly (p < 0.05) from baseline to week 12, except from physical activity, worries and depression.

At week 12 the level of physical activity and overall wellbeing were as in the background population.

16 (27%) patients with active inflammation (elevated CRP), both at baseline and week 12, did not have any significant improvement in HRQoL in the study period.

Conclusion

Intravenous iron infusion broadly improved HRQoL after 12 weeks in patients without active inflammation. This was not the case for patients with active inflammation. Inflammation seems to have a greater negative impact on HRQoL than the expected positive impact of intravenous iron infusions.